Urinary melatonin levels, sleep disruption, and risk of prostate cancer in elderly men.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsSigurdardottir, Lara G
Markt, Sarah C
Rider, Jennifer R
Schernhammer, Eva S
Tamimi, Rulla M
Batista, Julie L
Stampfer, Meir J
Czeisler, Charles A
Lockley, Steven W
Valdimarsdottir, Unnur A
Mucci, Lorelei A
MetadataShow full item record
CitationEur. Urol. 2015, 67 (2):191-4
AbstractMelatonin has anticarcinogenic properties in experimental models. We undertook a case-cohort study of 928 Icelandic men without prostate cancer (PCa) nested within the Age, Gene/Environment Susceptibility (AGES)-Reykjavik cohort to investigate the prospective association between first morning-void urinary 6-sulfatoxymelatonin (aMT6s) levels and the subsequent risk for PCa, under the hypothesis that men with lower aMT6s levels have an increased risk for advanced PCa. We used weighted Cox proportional hazards models to assess the association between first morning-void aMT6s levels and PCa risk, adjusting for potential confounders. A total of 111 men were diagnosed with incident PCa, including 24 with advanced disease. Men who reported sleep problems at baseline had lower morning aMT6s levels compared with those who reported no sleep problems. Men with morning aMT6s levels below the median had a fourfold statistically significant increased risk for advanced disease compared with men with levels above the median (hazard ratio: 4.04; 95% confidence interval, 1.26-12.98). These results require replication in larger prospective studies with longer follow-up.
In this report, we evaluated the prospective association between urinary aMT6s levels and risk of PCa in an Icelandic population. We found that lower levels of aMT6s were associated with an increased risk for advanced PCa.
DescriptionTo access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked Files. This article is open access.
RightsArchived with thanks to European urology
- Association of Urinary 6-Sulfatoxymelatonin (aMT6s) Levels and Objective and Subjective Sleep Measures in Older Men: The MrOS Sleep Study.
- Authors: Saksvik-Lehouillier I, Harrison SL, Marshall LM, Tranah GJ, Ensrud K, Ancoli-Israel S, Clemons A, Redline S, Stone KL, Schernhammer ES, Osteoporotic Fractures in Men (MrOS) Study Group.
- Issue date: 2015 Dec
- Association of urinary levels of 6-sulfatoxymelatonin (aMT6s) with prevalent and incident hypertension.
- Authors: Pérez-Caraballo AM, Ma Y, Ockene JK, Reeves KW, Balasubramanian R, Stanczyk FZ, Allison MA, Chen C, Wang L, Manson JE, Sturgeon SR
- Issue date: 2018 Aug
- Sleep disruption among older men and risk of prostate cancer.
- Authors: Sigurdardottir LG, Valdimarsdottir UA, Mucci LA, Fall K, Rider JR, Schernhammer E, Czeisler CA, Launer L, Harris T, Stampfer MJ, Gudnason V, Lockley SW
- Issue date: 2013 May
- Sleep duration, spot urinary 6-sulfatoxymelatonin levels and risk of breast cancer among Chinese women in Singapore.
- Authors: Wu AH, Stanczyk FZ, Wang R, Koh WP, Yuan JM, Yu MC
- Issue date: 2013 Feb 15
- Disruption of sleep, sleep-wake activity rhythm, and nocturnal melatonin production in breast cancer patients undergoing adjuvant chemotherapy: prospective cohort study.
- Authors: Li W, Kwok CC, Chan DC, Ho AW, Ho CS, Zhang J, Wing YK, Wang F, Tse LA
- Issue date: 2019 Mar